These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 745014)

  • 1. On the mode of action of L-deprenyl in the human central nervous system.
    Riederer P; Youdim MB; Rausch WD; Birkmayer W; Jellinger K; Seemann D
    J Neural Transm; 1978; 43(3-4):217-26. PubMed ID: 745014
    [No Abstract]   [Full Text] [Related]  

  • 2. Modification of substrate-inhibitor affinities of human platelet monoamine oxidase B in vitro.
    Szutowicz A; Tomaszewicz M; Orsulak PJ
    J Biol Chem; 1989 Oct; 264(30):17660-4. PubMed ID: 2509446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for existence of A and B form monoamine oxidase in mitochondria from dog platelets.
    Obata T; Egashira T; Yamanaka Y
    Jpn J Pharmacol; 1987 Jun; 44(2):105-11. PubMed ID: 3116304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of beta-phenylethylamine concentration on its substrate specificity for type A and type B monoamine oxidase.
    Suzuki O; Katsumata Y; Oya M; Matsumoto I
    Biochem Pharmacol; 1979 Mar; 28(6):953-6. PubMed ID: 454494
    [No Abstract]   [Full Text] [Related]  

  • 5. The reaction of bovine and rat liver monoamine oxidase with [14C]-clorgyline and [14C]-deprenyl.
    Salach JI; Detmer K; Youdim MB
    Mol Pharmacol; 1979 Jul; 16(1):234-41. PubMed ID: 481419
    [No Abstract]   [Full Text] [Related]  

  • 6. [Recent advances in studies on the specific inhibition and nature of monoamine oxidases (review)].
    Gorkin VZ
    Vopr Med Khim; 1982; 28(2):2-9. PubMed ID: 6805132
    [No Abstract]   [Full Text] [Related]  

  • 7. Dose regimen of deprenyl (selegiline) and platelet MAO activities.
    Oreland L; Johansson F; Ekstedt J
    Acta Neurol Scand Suppl; 1983; 95():87-9. PubMed ID: 6428150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[11C]deprenyl.
    Arnett CD; Fowler JS; MacGregor RR; Schlyer DJ; Wolf AP; Långström B; Halldin C
    J Neurochem; 1987 Aug; 49(2):522-7. PubMed ID: 3110375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use.
    Simpson GM; Frederickson E; Palmer R; Pi E; Sloane RB; White K
    Biol Psychiatry; 1985 Jun; 20(6):684-7. PubMed ID: 3922441
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of beta-fluorophenethylamine analogs on monoamine oxidase substrate preference.
    Meyerson LR; Fuller RW
    Res Commun Chem Pathol Pharmacol; 1978 Sep; 21(3):581-4. PubMed ID: 30122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications.
    Fowler CJ; Oreland L; Callingham BA
    J Pharm Pharmacol; 1981 Jun; 33(6):341-7. PubMed ID: 6115003
    [No Abstract]   [Full Text] [Related]  

  • 12. Monoamine oxidase activity during (--)-deprenil therapy: human brain post-mortem studies.
    Riederer P; Youdim MB; Birkmayer W; Jellinger K
    Adv Biochem Psychopharmacol; 1978; 19():377-82. PubMed ID: 696465
    [No Abstract]   [Full Text] [Related]  

  • 13. The possible mechanisms of action of (-)deprenyl in Parkinson's disease.
    Knoll J
    J Neural Transm; 1978; 43(3-4):177-98. PubMed ID: 745011
    [No Abstract]   [Full Text] [Related]  

  • 14. Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy.
    Lee DH; Mendoza M; Dvorozniak MT; Chung E; van Woert MH; Yahr MD
    J Neural Transm Park Dis Dement Sect; 1989; 1(3):189-94. PubMed ID: 2505797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
    Youdim MB
    J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.
    Zsilla G; Földi P; Held G; Székely AM; Knoll J
    Pol J Pharmacol Pharm; 1986; 38(1):57-67. PubMed ID: 3020531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidation of beta-phenylethylamine by both types of monoamine oxidase: effects of substrate concentration and pH.
    Suzuki O; Hattori H; Oya M; Katsumata Y; Matsumoto T
    Life Sci; 1979 Nov; 25(21):1843-50. PubMed ID: 43445
    [No Abstract]   [Full Text] [Related]  

  • 18. L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression.
    Mann J; Gershon S
    Life Sci; 1980 Mar; 26(11):877-82. PubMed ID: 6768943
    [No Abstract]   [Full Text] [Related]  

  • 19. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
    Severina IS
    Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyramine pressor sensitivity changes during deprenyl treatment.
    Sunderland T; Mueller EA; Cohen RM; Jimerson DC; Pickar D; Murphy DL
    Psychopharmacology (Berl); 1985; 86(4):432-7. PubMed ID: 3929314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.